Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632 1638 1641 1651 1655
This examiner grants 40% of resolved cases
Lauren K. Van Buren serves in Tech Center 1600 and Art Unit 1632, having completed 420 resolved cases. Her allowance rate is 39.8%, which suggests a challenging examination process for applicants. This 39.8% rate serves as a baseline for assessing the likelihood of a grant in this specific art unit. The 420 cases resolved by this examiner offer a reliable sample size for these performance metrics.
A critical data point for this examiner is the interview lift of 58.1%, which is exceptionally high. This figure indicates that conducting an interview is a highly effective strategy for moving an application toward allowance. Furthermore, the median days to allowance is 1546, suggesting a very long prosecution cycle. The high 58.1% lift suggests that the time spent in an interview can be a pivotal investment in overcoming the challenges that contribute to the 1546-day median pendency.
Practitioners should prioritize scheduling interviews early in the process given the 58.1% lift observed across 420 cases. While the 39.8% allowance rate indicates a rigorous review, the significant impact of verbal communication cannot be overlooked. The 1546-day median to allowance should be factored into the overall strategy, with the understanding that direct dialogue is a primary driver of success. This profile highlights the importance of active engagement in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18029354 | METHOD FOR CRYOPRESERVING A PLURALITY OF CELL CLUSTERS OF BIOLOGICAL CELLS | Final Rejection | Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e. V. |
| 17291536 | PROCESS FOR PRODUCING GENETICALLY ENGINEERED T CELLS | Final Rejection | Juno Therapeutics, Inc. |
| 18558065 | STRING-LIKE AGGREGATES OF RETINAL PIGMENT EPITHELIAL CELLS, DEVICE AND PRODUCTION METHOD FOR PRODUCING SAME, AND THERAPEUTIC AGENT COMPRISING SAID STRING-LIKE AGGREGATES | Final Rejection | RIKEN |
| 18283272 | METHODS AND COMPOSITIONS FOR ACCELERATING OLIGODENDROCYTE MATURATION | Non-Final OA | Case Western Reserve University |
| 16089918 | METHOD OF PRODUCING SUGAR LIQUID | Final Rejection | Toray Industries, Inc. |
| 18124110 | METHODS AND COMPOSITIONS FOR INHIBITING ICE RECRYSTALLIZATION | Final Rejection | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION |
| 17440991 | Enhanced Transfection | Final Rejection | The University of Nottingham |
| 18018389 | CELL CULTURE MEDIA AND METHODS OF MAKING AND USING THE SAME | Final Rejection | AMGEN INC. |
| 19028696 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING AND PREVENTING HALITOSIS | Final Rejection | Imvela Corp. |
| 18790185 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING AND PREVENTING HALITOSIS | Non-Final OA | Imvela Corp. |
| 18105204 | TISSUE-ENGINEERED INTERVERTEBRAL DISC WITH LIVING CELLS | Final Rejection | Cornell University |
| 17642809 | HER3 PULSED DC1 THERAPY | Final Rejection | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18648199 | METHODS OF IMPROVING RAAV PRODUCTION | Non-Final OA | Genzyme Corporation |
| 18044955 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | Final Rejection | BioNTech SE |
| 18060626 | HISTAMINE-PRODUCING BACTERIAL STRAINS AND THEIR USE IN CANCER | Final Rejection | BIOGAIA AB |
| 18270924 | CELLULAR MICROCOMPARTMENTS COMPRISING CELLS OF WHICH THE GENOMIC INTEGRITY IS MAINTAINED AFTER AMPLIFICATION AND PREPARATION METHOD | Final Rejection | TREEFROG THERAPEUTICS |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy